Biohaven signs $795 million epilepsy drug licensing deal
Biohaven signed an epilepsy drug licensing deal with SK Biopharm valued at $795 million, per TradingView News.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.